GTMTX
Price
$24.50
Change
-$0.02 (-0.08%)
Updated
Nov 13 closing price
PMAQX
Price
$48.46
Change
+$0.16 (+0.33%)
Updated
Nov 13 closing price
Ad is loading...

GTMTX vs PMAQX

Header iconGTMTX vs PMAQX Comparison
Open Charts GTMTX vs PMAQXBanner chart's image
Goldman Sachs Small/Mid Cap Growth I
Price$24.50
Change-$0.02 (-0.08%)
VolumeN/A
CapitalizationN/A
Principal MidCap R6
Price$48.46
Change+$0.16 (+0.33%)
VolumeN/A
CapitalizationN/A
GTMTX vs PMAQX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GTMTX vs. PMAQX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTMTX is a StrongBuy and PMAQX is a Buy.

FUNDAMENTALS
Fundamentals
PMAQX has more cash in the bank: 29.8B vs. GTMTX (1.87B). PMAQX pays higher dividends than GTMTX: PMAQX (0.10) vs GTMTX (0.00). GTMTX was incepted earlier than PMAQX: GTMTX (17 years) vs PMAQX (8 years). GTMTX is a more actively managed with annual turnover of: 62.00 vs. PMAQX (10.10). GTMTX (0) and PMAQX (0) have matching initial minimum investment requirements. GTMTX (32.83) and PMAQX (32.12) have marching annual gain over last year. PMAQX return over 5 years is better than : 55.10 vs. GTMTX (9.71).
GTMTXPMAQXGTMTX / PMAQX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence17 years8 years-
Gain YTD18.85626.39571%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets1.87B29.8B6%
Annual Yield % from dividends0.000.10-
Returns for 1 year32.8332.12102%
Returns for 3 years-22.706.88-330%
Returns for 5 years9.7155.1018%
Returns for 10 years11.66N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LIXT1.65-0.03
-1.79%
Lixte Biotechnology Holdings
ATRO16.49-0.38
-2.25%
Astronics Corp
LFST7.22-0.18
-2.43%
LifeStance Health Group
CVNA239.98-6.77
-2.74%
Carvana Co
IPSC1.33-0.08
-5.67%
Century Therapeutics